Top Markets
#1 Black Phoenix Black Phoenix +733.86%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.97%
#3 Wrapped STX (Velar) Wrapped STX (Velar) +16.84%
#4 MetaDAO MetaDAO +16.83%
#5 Verus Coin Verus Coin +13.94%
#6 Akedo Akedo +10.08%
#7 Derive Derive +9.22%
#8 Tokamak Network Tokamak Network +6.40%
#9 XYO Network XYO Network +5.56%
#10 Cysic Cysic +5.30%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
MBX Biosciences, Inc. Common Stock MBX Biosciences, Inc. Common Stock

MBX Biosciences, Inc. Common Stock

MBX
Classifica tra le azioni #4855
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical... MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
Prezzo delle azioni
$67.63
Ultima sincronizzazione: 2026-08-26
Capitalizzazione di mercato
$3.22B
Variazione (1 giorno)
-1.45%
Variazione (1 anno)
372.57%
Paese
US
Scambia MBX Biosciences, Inc. Common Stock (MBX)

Categoria

Healthcare
Margine operativo per MBX Biosciences, Inc. Common Stock (MBX)
Margine operativo al 2026 TTM: 0.00%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di MBX Biosciences, Inc. Common Stock, il margine operativo attuale (TTM) è 0.00%. Alla fine del 2026, il margine operativo era 0.00%.
Storico del margine operativo per MBX Biosciences, Inc. Common Stock da 2026 a 2026
Margine operativo alla fine di ogni anno
Anno Margine Operativo Cambia
Non abbastanza dati per le date fornite.
Margine operativo per aziende simili o concorrenti
Azienda Margine Operativo Differenza del margine operativo Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.